Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
May 26 2009 - 7:00AM
PR Newswire (US)
-- Conference Call Scheduled for Monday June 1 at 1:00 PM ET to
Discuss ASCO Data Presentations -- SOUTH SAN FRANCISCO, Calif., May
26 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc.
(NASDAQ:SNSS), a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics,
today announced that updated interim data from the Company's
ongoing Phase 2 clinical trials in frontline acute myeloid leukemia
(AML) and platinum-resistant ovarian cancer and its Phase 1b/2
clinical trial in relapsed/refractory AML will be presented during
the American Society of Clinical Oncology (ASCO) 2009 Annual
Meeting in Orlando, Florida, which begins May 29, 2009. Following
are the details on each of these data presentations. Saturday May
30, 8:00AM to 12:00PM (poster presentation) Abstract #7048 Title:
"A phase II study of voreloxin as single agent therapy for elderly
patients (pts) with newly diagnosed acute myeloid leukemia (AML)."
Location: Level 2, West Hall C Board #M2 Sunday May 31, 2:00PM to
6:00PM (poster presentation) Abstract #5559 Title: "A phase II
trial of voreloxin in women with platinum-resistant ovarian
cancer." Location: Level 2, West Hall C Board #M18 Monday June 1,
10:30AM (oral presentation) Abstract #7005 Title: "Phase Ib/II
pharmacokinetic/pharmacodynamic (PK/PD) study of combination
voreloxin and cytarabine in relapsed or refractory AML patients."
Location: Level 2, West Hall F1 Additionally at the ASCO 2009
Annual Meeting, Sunesis will be presenting clinical data on
SNS-314, a novel and selective pan-Aurora kinase inhibitor. Details
of this presentation are below. Saturday May 30, 8:00AM to 12:00PM
(poster presentation) Abstract #2536 Title: "A phase I trial of
SNS-314, a novel and selective pan-aurora kinase inhibitor, in
advanced solid tumor patients." Location: Level 2, West Hall C
Board #A7 All of these presentations will be available on the
Sunesis website at http://www.sunesis.com/ on the same day each is
presented. Conference Call Information Sunesis management, joined
by voreloxin clinical investigators, will host a conference call to
discuss the voreloxin clinical data presented at the ASCO 2009
Annual Meeting on Monday June 1, 2009, at 1:00 p.m. ET / 10:00 a.m.
PT. Individual and institutional investors can access the call via
1-877-856-1961 (U.S. and Canada) or +1-719-325-4787
(international). To access the live audio webcast or the subsequent
archived recording, visit the "Investors and Media - Calendar of
Events" section of the Sunesis website at http://www.sunesis.com/.
The webcast will be recorded and available for replay on the
company's website until June 15, 2009. About Voreloxin Voreloxin is
a first-in-class anticancer quinolone derivative, or AQD, a class
of compounds that has not been used previously for the treatment of
cancer. Voreloxin both intercalates DNA and inhibits topoisomerase
II, resulting in replication-dependent, site-selective DNA damage,
G2 arrest and apoptosis. Voreloxin is currently being evaluated in
a Phase 2 clinical trial (known as the REVEAL-1 trial) in
previously untreated elderly AML patients and in a Phase 1b/2
clinical trial combining voreloxin with cytarabine for the
treatment of patients with relapsed/refractory AML, as well as in
an ongoing Phase 2 single-agent trial in platinum-resistant ovarian
cancer. About Acute Myeloid Leukemia AML is a rapidly progressing
cancer of the blood characterized by the uncontrolled proliferation
of immature blast cells in the bone marrow. The Leukemia and
Lymphoma Society estimates that over 13,000 new cases of AML were
diagnosed and approximately 9,000 deaths from AML occurred in the
U.S. during 2007. AML is generally a disease of older adults, and
the median age of a patient diagnosed with AML is about 67 years. A
majority of elderly patients are not considered candidates for
standard induction therapy or decline therapy, resulting in an
acute need for new treatment options. About Ovarian Cancer In the
United States, ovarian cancer remains the leading cause of death
from gynecologic malignancies and is the fifth leading cause of
cancer death overall in women behind lung, breast, colorectal and
pancreatic cancers. According to the American Cancer Society, in
2008 there were an estimated 21,650 new cases and more than 15,000
deaths from ovarian cancer in the U.S. alone. Following frontline
treatment, recurrence rates among ovarian cancer patients are high.
Treatment options remain limited following relapse, and overall
long-term survival has not changed significantly over the past 40
years, with five-year survival rates at less than 30 percent. About
Sunesis Pharmaceuticals Sunesis is a biopharmaceutical company
focused on the development and commercialization of new oncology
therapeutics for the treatment of solid and hematologic cancers.
Sunesis has built a highly experienced cancer drug development
organization committed to advancing its lead product candidate,
voreloxin, in multiple indications to improve the lives of people
with cancer. For additional information on Sunesis Pharmaceuticals,
please visit http://www.sunesis.com/. SUNESIS and the logo are
trademarks of Sunesis Pharmaceuticals, Inc. Investor Contact: Media
Contact: Sunesis Pharmaceuticals, Inc. Sunesis Pharmaceuticals,
Inc. Eric Bjerkholt Dan Weinseimer 650-266-3717 650-266-3739
DATASOURCE: Sunesis Pharmaceuticals, Inc. CONTACT: Investors, Eric
Bjerkholt, +1-650-266-3717, or Media, Dan Weinseimer,
+1-650-266-3739, both of Sunesis Pharmaceuticals, Inc. Web Site:
http://www.sunesis.com/
Copyright
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024